PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-18.36%
Negative revenue growth while CVE stands at 4.93%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-39.33%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-66.67%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-66.67%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-75.16%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-75.00%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-75.00%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
0.07%
Share count expansion well above CVE's 0.07%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
No Data
No Data available this quarter, please select a different quarter.
0.27%
Dividend growth of 0.27% while CVE is flat. Bruce Berkowitz would see if this can become a bigger advantage long term.
6.77%
OCF growth under 50% of CVE's 16.28%. Michael Burry might suspect questionable revenue recognition or rising costs.
255.33%
FCF growth under 50% of CVE's 913.33%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
161.72%
10Y CAGR of 161.72% while CVE is zero. Bruce Berkowitz would see if incremental growth can widen into a significant edge.
69.53%
5Y CAGR of 69.53% while CVE is zero. Bruce Berkowitz would see if small improvements can scale into a larger advantage.
9.12%
3Y CAGR of 9.12% while CVE is zero. Bruce Berkowitz would see if small gains can accelerate to a more decisive lead.
426.71%
OCF/share CAGR of 426.71% while CVE is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
200.57%
OCF/share CAGR of 200.57% while CVE is zero. Bruce Berkowitz would see if modest momentum can translate into a bigger competitive lead.
-7.17%
Negative 3Y OCF/share CAGR while CVE stands at 0.00%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-2.45%
Negative 10Y net income/share CAGR while CVE is at 0.00%. Joel Greenblatt sees a major red flag in long-term profit erosion.
17.10%
Net income/share CAGR of 17.10% while CVE is zero. Bruce Berkowitz would see if small mid-term gains can develop into a bigger lead.
-87.77%
Negative 3Y CAGR while CVE is 0.00%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
248.34%
Equity/share CAGR of 248.34% while CVE is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
160.40%
Equity/share CAGR of 160.40% while CVE is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
48.09%
Equity/share CAGR of 48.09% while CVE is zero. Bruce Berkowitz sees if minor gains can snowball into a bigger lead soon.
899.39%
Dividend/share CAGR of 899.39% while CVE is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
701.10%
Dividend/share CAGR of 701.10% while CVE is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
305.19%
3Y dividend/share CAGR of 305.19% while CVE is zero. Bruce Berkowitz sees a minor positive difference that could attract dividend-focused investors.
6.92%
AR growth of 6.92% while CVE is zero. Bruce Berkowitz wonders if the firm’s additional AR is warranted by strong revenue or potential risk.
32.46%
Inventory growth of 32.46% while CVE is zero. Bruce Berkowitz wonders if we anticipate a new wave of demand or risk being stuck with extra product.
1.58%
Asset growth of 1.58% while CVE is zero. Bruce Berkowitz checks if modest expansions can create a longer-term lead.
3.69%
BV/share growth of 3.69% while CVE is zero. Bruce Berkowitz sees if small growth can compound into a strong advantage.
-5.34%
We’re deleveraging while CVE stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
No Data
No Data available this quarter, please select a different quarter.
41.18%
We expand SG&A while CVE cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.